Medigen Biotechnology (3176) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medigen Biotechnology (3176) has a cash flow conversion efficiency ratio of -0.004x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-18.91 Million ≈ $-595.86K USD) by net assets (NT$4.90 Billion ≈ $154.29 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Medigen Biotechnology market capitalisation for the company's overall valuation and market capitalisation.
Medigen Biotechnology - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Medigen Biotechnology's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Medigen Biotechnology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medigen Biotechnology ranked by their cash flow conversion efficiency. Explore Medigen Biotechnology (3176) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
United Pharm
KO:033270
|
0.077x |
|
TON Strategy Co
NASDAQ:TONX
|
-0.015x |
|
James River Group Holdings Ltd
NASDAQ:JRVR
|
-0.008x |
|
Shangri-La Hotel Public Company Limited
BK:SHANG
|
0.013x |
|
Kolibri Global Energy Inc
TO:KEI
|
0.033x |
|
Spandana Sphoorty Financial Limited
NSE:SPANDANA
|
0.597x |
|
China Ecotek Corp
TW:1535
|
0.170x |
|
BV Financial, Inc. Common Stock
NASDAQ:BVFL
|
0.019x |
Annual Cash Flow Conversion Efficiency for Medigen Biotechnology (2003–2024)
The table below shows the annual cash flow conversion efficiency of Medigen Biotechnology from 2003 to 2024. View 3176 stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$5.04 Billion ≈ $158.73 Million |
NT$37.92 Million ≈ $1.19 Million |
0.008x | +106.61% |
| 2023-12-31 | NT$5.00 Billion ≈ $157.44 Million |
NT$-569.40 Million ≈ $-17.94 Million |
-0.114x | +34.61% |
| 2022-12-31 | NT$6.47 Billion ≈ $203.87 Million |
NT$-1.13 Billion ≈ $-35.53 Million |
-0.174x | -316.41% |
| 2021-12-31 | NT$6.43 Billion ≈ $202.46 Million |
NT$517.45 Million ≈ $16.30 Million |
0.081x | +153.97% |
| 2020-12-31 | NT$4.50 Billion ≈ $141.76 Million |
NT$-671.38 Million ≈ $-21.15 Million |
-0.149x | +28.47% |
| 2019-12-31 | NT$2.69 Billion ≈ $84.60 Million |
NT$-560.17 Million ≈ $-17.65 Million |
-0.209x | -15.80% |
| 2018-12-31 | NT$2.94 Billion ≈ $92.66 Million |
NT$-529.82 Million ≈ $-16.69 Million |
-0.180x | -25.74% |
| 2017-12-31 | NT$3.18 Billion ≈ $100.19 Million |
NT$-455.62 Million ≈ $-14.35 Million |
-0.143x | -8.16% |
| 2016-12-31 | NT$3.54 Billion ≈ $111.46 Million |
NT$-468.61 Million ≈ $-14.76 Million |
-0.132x | -255.98% |
| 2015-12-31 | NT$3.46 Billion ≈ $109.14 Million |
NT$294.18 Million ≈ $9.27 Million |
0.085x | -31.58% |
| 2005-12-31 | NT$650.39 Million ≈ $20.49 Million |
NT$80.72 Million ≈ $2.54 Million |
0.124x | -76.13% |
| 2003-12-31 | NT$856.65 Million ≈ $26.99 Million |
NT$445.46 Million ≈ $14.03 Million |
0.520x | -- |
About Medigen Biotechnology
Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has complete… Read more